These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24291969)

  • 41. Validation of the italian version of the 15-item Myasthenia Gravis Quality-of-Life questionnaire.
    Raggi A; Leonardi M; Ayadi R; Antozzi C; Maggi L; Baggi F; Mantegazza R
    Muscle Nerve; 2017 Oct; 56(4):716-720. PubMed ID: 28029697
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of Myasthenia Gravis With High-Dose Cholinesterase Inhibitors and Calcineurin Inhibitors Caused Spontaneous Muscle Cramps in Patients.
    Masuda M; Utsumi H; Tanaka S; Maeno A; Yamamoto M; Sugiyama K; Hirano T; Aizawa H
    Clin Neuropharmacol; 2018; 41(5):164-170. PubMed ID: 30130259
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Validation of the 15-item myasthenia gravis quality of life questionnaire (MG-QOL15) Persian version.
    Ostovan VR; Fatehi F; Davoudi F; Nafissi S
    Muscle Nerve; 2016 Jun; 54(1):65-70. PubMed ID: 26661455
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.
    Bourque PR; Pringle CE; Cameron W; Cowan J; Chardon JW
    PLoS One; 2016; 11(8):e0159993. PubMed ID: 27490101
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone.
    Shimojima Y; Matsuda M; Gono T; Ishii W; Tokuda T; Ikeda S
    J Clin Neurosci; 2006 Jan; 13(1):39-44. PubMed ID: 16307880
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Translation, cross-cultural adaptation, and validation of the french version of the 15-item Myasthenia Gravis Quality Of life scale.
    Birnbaum S; Ghout I; Demeret S; Bolgert F; Eymard B; Sharshar T; Portero P; Hogrel JY
    Muscle Nerve; 2017 May; 55(5):639-645. PubMed ID: 27533497
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunosuppressive agents for myasthenia gravis.
    Hart IK; Sathasivam S; Sharshar T
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005224. PubMed ID: 17943844
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pneumatosis intestinalis in a patient of myasthenia gravis treated with high-dose corticosteroid].
    Kameyama K; Noguchi Y; Matsumoto T; Takenawa H; Fujigasaki H; Kanda T; Mizusawa H
    Rinsho Shinkeigaku; 2003 May; 43(5):277-80. PubMed ID: 12931635
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Massive prednisolone administration in myasthenia gravis--electrophysiological examination].
    Yanagizawa N; Shoji S; Tsukagoshi H; Toyokura Y
    Nihon Rinsho; 1973 Feb; 31(2):321-6. PubMed ID: 4737112
    [No Abstract]   [Full Text] [Related]  

  • 50. Intermittent long-term adrenocorticosteroid treatment of myasthenia gravis.
    Wakata N; Kawamura Y; Kobayashi M; Araki Y; Kinoshita M
    J Neurol; 1991 Feb; 238(1):16-8. PubMed ID: 2030367
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The modified rankin scale to assess disability in myasthenia gravis: Comparing with other tools.
    Farrugia ME; Carmichael C; Cupka BJ; Warder J; Brennan KM; Burns TM
    Muscle Nerve; 2014 Oct; 50(4):501-7. PubMed ID: 24639179
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus.
    Nagaishi A; Yukitake M; Kuroda Y
    Intern Med; 2008; 47(8):731-6. PubMed ID: 18421189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bone density in myasthenia gravis patients receiving long-term prednisolone therapy.
    Wakata N; Nemoto H; Sugimoto H; Nomoto N; Konno S; Hayashi N; Araki Y; Nakazato A
    Clin Neurol Neurosurg; 2004 Mar; 106(2):139-41. PubMed ID: 15003307
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of Early Treatment with Intravenous High-Dose Methylprednisolone for Ocular Myasthenia Gravis.
    Uzawa A; Suzuki S; Kuwabara S; Akamine H; Onishi Y; Yasuda M; Ozawa Y; Kawaguchi N; Kubota T; Takahashi MP; Suzuki Y; Watanabe G; Kimura T; Sugimoto T; Samukawa M; Minami N; Masuda M; Konno S; Nagane Y; Utsugisawa K
    Neurotherapeutics; 2023 Mar; 20(2):518-523. PubMed ID: 36607596
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quality of Life in Myasthenia Gravis and Correlation of MG-QOL15 with Other Functional Scales.
    Diez Porras L; Homedes C; Alberti MA; Velez Santamaria V; Casasnovas C
    J Clin Med; 2022 Apr; 11(8):. PubMed ID: 35456281
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study.
    Chen P; Feng H; Deng J; Luo Y; Qiu L; Ou C; Liu W
    J Neurol; 2016 Jan; 263(1):83-8. PubMed ID: 26514837
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of outcome measures for myasthenia gravis subgroups.
    Luo Y; Dong X; Peng Y; Cui B; Yan C; Jin W; Li Y; Zhou R; Huang K; Yang H
    J Clin Neurosci; 2021 Sep; 91():270-275. PubMed ID: 34373039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Myasthenia Gravis-specific Activities of Daily Living scale as a useful outcome measure and in routine clinical management in Polish patients.
    Rozmilowska IM; Adamczyk-Sowa MH; Czyzewski D
    Neurol Neurochir Pol; 2018; 52(3):368-373. PubMed ID: 29370887
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study.
    Nagane Y; Utsugisawa K; Obara D; Kondoh R; Terayama Y
    Eur Neurol; 2005; 53(3):146-50. PubMed ID: 15900097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.